Russia has produced import-replacing analogues for 88 pharmaceutical substances, accounting for nearly half of the volume planned for the period up to 2030, according to Deputy Minister of Industry and Trade Ekaterina Priezzheva. The ministry is also expanding its support program for the development of drugs still under patent protection. To date, Russia has achieved import substitution for 88 active pharmaceutical ingredients, said Deputy Minister of Industry and Trade Ekaterina Priezzheva at a session on “Components of Security: The Contribution of Every Link in the Pharmaceutical Industry,” held on March 17, 2026, as part of the Healthy Society forum. According to her, 294 marketing authorizations have been issued for these substances.
“In total, by 2030, Russia must establish production of 186 international nonproprietary names that were not previously manufactured in the country,” Priezzheva reminded the audience.
The official also noted that more than half of the 186 active substances are protected by patents.
“However, to address this issue, we have the ‘Products for the Shelves’ program, which provides support to Russian pharmaceutical companies for the development and registration of drugs that are under patent protection,” Priezzheva emphasized.
The Deputy Minister added that the Ministry of Industry and Trade has already coordinated the third round of competitive selections with the Ministry of Health for the list of drugs that will be added to this program. It will include 33 medications.
In March 2024, Ekaterina Priezzheva announced the launch of the second list of drugs for which pharmaceutical manufacturers could receive subsidies for development under the “Products on the Shelf” program. The first list, which included 25 INNs, was published in December 2023.
The Deputy Minister of Industry and Trade also reported that a project aimed at supporting innovative drug manufacturers is currently under review. She stressed that under this project, it is planned to extend the investment phase for biotech companies to five years.
